Metastatic Solid Tumor Clinical Trials in New York, New York

17 studies are recruiting for metastatic solid tumor in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Memorial Sloan Kettering, New York, New York

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

   This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York

   Locations

   18 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT05898399 on ClinicalTrials.gov

3. GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York

   Locations

   13 in total

   Run by

   GI Innovation, Inc.

   See if you can join NCT04977453 on ClinicalTrials.gov

4. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

   The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06561685 on ClinicalTrials.gov

5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

6. A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

   The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05837767 on ClinicalTrials.gov

7. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #103, New York, New York

   Locations

   18 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06545942 on ClinicalTrials.gov

8. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

   The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   30 in total

   Run by

   Coherus Oncology, Inc.

   See if you can join NCT06657144 on ClinicalTrials.gov

9. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

   This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #7, New York, New York

   Locations

   11 in total

   Run by

   Exelixis

   See if you can join NCT06952010 on ClinicalTrials.gov

10. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

    The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07638371 on ClinicalTrials.gov

11. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

    A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, New York, New York

    Locations

    10 in total

    Run by

    Plexium, Inc.

    See if you can join NCT07284186 on ClinicalTrials.gov

12. A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

    This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors. We researchers will try to find the highest dose of the study drug that causes few or mild side…

    Stage

    Phase 1

    Ages

    1 to 25

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05004116 on ClinicalTrials.gov

13. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evalu…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

    Locations

    74 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT05384626 on ClinicalTrials.gov

14. A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

    Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-sm…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    21 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT06521554 on ClinicalTrials.gov

15. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

16. A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

    Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid …

    Stage

    Phase 1

    Ages

    12 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    63 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT05118789 on ClinicalTrials.gov

17. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan-Kettering Cancer Center, New York, New York

    Locations

    11 in total

    Run by

    GI Innovation, Inc.

    See if you can join NCT05824975 on ClinicalTrials.gov